INTRODUCTION {#sec1}
============

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, previously named 2019 novel coronavirus or 2019-nCoV) has spread for several month since December 2019. The SARS-CoV-2 virus is a betacoronavirus, which includes Middle East respiratory syndrome CoV (MERS-CoV) and severe acute respiratory syndrome CoV (SARS-CoV). SARS-CoV-2 shares 95% sequence identity with a bat coronavirus, indicating that bats are likely the reservoir hosts for the virus (Zhou *et al*. [@bib39]) and pangolins are possible intermediate hosts for SARS-CoV-2 (Lam *et al*. [@bib14]). Both SARS-CoV-2 and SARS-CoV use angiotensin-converting enzyme II (ACE2) as the cell entry receptor (Walls *et al*. [@bib28]; Wang *et al*. [@bib29]; Zhou *et al*. [@bib39]). The genome of SARS-CoV-2 encodes nonstructural enzymes (such as 3-chymotrypsin-like protease (3CLpro), papain-like protease (PLpro), helicase and RNA-dependent RNA polymerase (RdRp)) and structural and accessory proteins (such as spike glycoprotein, envelope protein, matrix protein, nucleocapsid protein) (Ashour *et al*. [@bib2]; Li and De Clercq [@bib16]).

The disease caused by SARS-CoV-2 is named coronavirus disease 2019 (COVID-19). SARS-CoV-2 can infect the upper and lower respiratory tracts of humans, and infection with SARS-CoV-2 can initiates severe and life-threatening pneumonia, probably causing the development of acute lung injury (ALI) and acute respiratory distress syndrome (ARDS). The major initial symptoms of COVID-19 include fever, cough, muscle pain or fatigue and lymphopenia (Guan *et al*. [@bib10]; Liu *et al*. [@bib21]). SARS-CoV-2 is highly contagious, as the basic reproduction number, R0, is approximately 2--3.5, as previously reported (Ashour *et al*. [@bib2]; Zhao *et al*. [@bib38]).

Although approximately 90 antiviral drugs have been approved for the treatment of nine kinds of human infectious disease (De Clercq and Li [@bib6]), there are currently no vaccines or therapeutic drugs to prevent SARS-CoV-2 infection. Therefore, the prevention and treatment of COVID-19 is urgently needed worldwide. Drug repositioning is an efficient approach to tackle this problem. By integrating several aspects of the drugs, diseases and target, drug repositioning could produce convincing predictions, reducing the drug development cost and time (Wang *et al*. [@bib33], [@bib30], [@bib32]). Several researchers have used molecular docking, high-throughput screening, network analysis or knowledge graphs to search for effective drugs (Ge *et al*. [@bib8]; Matsuyama *et al*. [@bib22]). Cepharanthine, selamectin and mefloquine hydrochloride were identified as potential drugs for treating 2019-nCoV infection using a pangolin coronavirus-based cell model (Fan *et al*. [@bib7]). Teicoplanin, a glycopeptide antibiotic, potently prevents cell entry by SARS-CoV-2 (Zhang *et al*. [@bib37]). Prulifloxacin, bictegravir, nelfinavir and tegobuvir were found to tightly bind to the viral 3CLpro in an in silico high-throughput screening assay. Nelfinavir and bictegravir are anti-HIV drugs, and tegobuvir is an anti-HCV drug (Li *et al*. [@bib18]). Moreover, nelfinavir has been shown to inhibit viral 3CLpro via an integrative strategy combining homology modeling, molecular docking and binding free energy calculation.

However, there has been no transcriptome-based drug repositioning for COVID-19, which has been proven to be an efficient way to discover candidate drugs for diseases (Jahchan *et al*. [@bib11]; Wang *et al*. [@bib33]; Wu, Wang and Chen [@bib34]; Arakelyan *et al*. [@bib1]) and can be considered as a orthogonal and complementary method. We used bronchoalveolar lavage fluid (BALF) transcriptomics data from 8 COVID-19 patients and 20 healthy controls to explore the gene expression signature of the disease and applied a coexpression-based drug repositioning pipeline, which we previously developed, to search for candidate drugs for COVID-19. Consequently, we recovered two antiviral drugs, saquinavir and ribavirin, and identified several candidate drugs for treating COVID-19 pneumonia.

MATERIALS AND METHODS {#sec2}
=====================

Transcriptomic data of COVID-19 patients and healthy controls {#sec2-1}
-------------------------------------------------------------

The BALF of 8 COVID-19 patients (COVID) and healthy controls (healthy) were used to extract RNA and prepare a library for HiSeq sequencing, and data quality control, mapping and gene quantitation were performed as described in a previous work (Zhou *et al*. [@bib40]). The raw data were deposited in the Genome Warehouse in the National Genomics Data Center (Members, B.I.G.D.C [@bib23]) available at <https://bigd.big.ac.cn/gsa> with project number PRJCA002273.

Differential expression analysis {#sec2-2}
--------------------------------

The raw read counts were filtered to identify low-expressed genes using the filterByExpr function in the Bioconductor edgeR package (Robinson, McCarthy and Smyth [@bib26]), normalized using quantile normalization, and the voom method in the Bioconductor limma package (Ritchie *et al*. [@bib25]). Then, differential expression analysis for the COVID and healthy groups was implemented based on the normalized gene expression level by absolute logged fold-change in normalized expression ≥ 2 and an adjusted *P*-value of \< 0.05 to obtain differentially expressed genes (DEGs). Principal components analysis (PCA) was used to visualize the differences between two groups.

Computational drug repositioning analysis {#sec2-3}
-----------------------------------------

The KEGG pathway analysis, Reactome pathway analysis and drug repositioning for the coexpressed genes were performed via the cogena package, previously developed by one of the authors (Jia *et al*. [@bib12]). The KEGG and Reactome gene sets were used in the pathway analysis (Liberzon *et al*. [@bib19]), and the drug-induced transcriptome in the connectivity map project (Lamb *et al*. [@bib15]) was used in the cogena-based drug repositioning analysis. A core concept of cogena for drug repositioning is that identifying drugs that can revert the regulation direction of coexpressed DEGs caused by a disease and the connection between coexpressed DEGs, pathways and drugs can be used to uncover the drug mechanism of action for the treatment of the disease. In the drug repositioning analysis, a drug-induced upregulated gene set was used for the downregulated gene cluster, and a drug-induced downregulated gene set was used for the upregulated gene cluster. Particularly, the clustering method and the number of clusters were chosen using several rules, as described in the original cogena paper. Briefly, similar pathways should be enriched in a cluster, and different pathways should be enriched in different clusters. The enrichment score is the negative log2 false-discovery rate (FDR)-corrected p-value obtained via the hypergeometric test.

RESULTS AND DISCUSSION {#sec3}
======================

Differentially expressed genes clearly distinguish the COVID and healthy groups {#sec3-1}
-------------------------------------------------------------------------------

The use of lower respiratory tract specimens, such as the BALF, is important to explore the mechanisms of disease development, as the disease mainly affects the lower respiratory tract, especially the lungs. To identify the key genes affected by COVID-19, we performed a transcriptomics differential expression analysis and identified a total of 1569 differentially expressed genes (DEGs), consisting of 872 genes with upregulated expression and 697 genes with downregulated expression (Figure S1 and Table S1, Supporting Information). The two groups could be clearly separated with all the genes (Figure S2, Supporting Information) or all the DEGs (Fig. [1A](#fig1){ref-type="fig"}) in the principal component analysis. A heatmap of these DEGs with hierarchical clustering of both the samples and genes indicated that the two groups differed from each other, as the COVID samples closely clustered and the healthy samples clustered together (Fig. [1B](#fig1){ref-type="fig"}). The Pearson correlation between samples also presented high consistency within each group, whereas there was a marked difference between the two groups (Fig. [1C](#fig1){ref-type="fig"}). As a result, the identified DEGs are representative of COVID.

![General analysis of COVID-19-induced DEGs. **(A)** The first two dimensions of the principal components analysis for the DEGs of COVID-19. PC1 and PC2 are principal components 1 and 2, respectively. **(B)** Heatmap and hierarchical clustering of DEGs. C1-C8 represent the samples of COVID-19 patients, and H1-H20 represent healthy controls. The values are shown as the normalized gene expression. **(C)** Correlation between all the samples. The size of the circle represents the absolute Pearson correlation coefficient, and color indicates the direction of the correlation.](ftaa036fig1){#fig1}

Functional analysis of coexpressed genes {#sec3-2}
----------------------------------------

Coexpressed genes usually cooperate to implement similar functions, which is a specific way to connect key genes among DEGs with diseases and could provide an important clue to understand the pathogenesis of a disease. Three clusters of coexpressed genes were obtained via a divisive hierarchical clustering method, DIANA (Figure S3 and Table S2, Supporting Information). Compared with that of genes in the healthy group, the expression of coexpressed genes in cluster 1 in the COVID groups was increased, whereas the expression of others was decreased (Fig. [2A](#fig2){ref-type="fig"} and Figure S3, Supporting Information). The KEGG pathway enrichment analysis for coexpressed genes is shown in Fig. [2B](#fig2){ref-type="fig"}. Ribosome, chemokine signaling and endocytosis pathways were enriched in cluster 1. Generally, endocytosis or micropinocytosis plays a role in viral entrance into the early endosomes in cells (Zhang *et al*. [@bib37]). Lysosome, renin-angiotensin system and asthma pathways were enriched in cluster 2, and calcium and MAPK signaling pathways were enriched in cluster 3. Lysosomes are involved in destroying invading viruses, and the downregulation of lysosome-associated gene expression suggests dysregulation of the innate immune system. This finding is consistent with the downregulation of the expression of lysosomal genes reported by Xiong *et al*. ([@bib35]).

![Coexpression analysis. **(A)** Coexpression trend in the samples. Three clusters determined by the DIANA clustering method are shown. **(B)** KEGG pathway analysis for coexpressed genes generated by cogena. The color indicates the degree of statistical significance, and the enrichment score is the -log (*q*-value). **(C)** Heatmap of genes in the neutrophil degranulation Reactome pathway. C1--C8 represent the samples of COVID-19 patients, and H1-H20 represent the samples of healthy controls. The values are shown as the normalized gene expression.](ftaa036fig2){#fig2}

In the Reactome analysis (Figure S4, Supporting Information), neutrophil degranulation and the innate immune system were enriched in both clusters 1 (upregulated genes) and 2 (downregulated genes). Interestingly, neutrophils, the proportion of which was higher in the COVID group than in the healthy control group, play a role in the response to viral infection (Liu *et al*. [@bib20]). Neutrophil degranulation was not fully activated or was partly blocked by the virus, as the expression of approximately half of the genes in this pathway was downregulated (Fig. [2C](#fig2){ref-type="fig"}). The coexpression pathway analysis revealed that a large gene expression change was induced by COVID to facilitate the viral life cycle.

Computational drug repositioning for COVID-19 pneumonia {#sec3-3}
-------------------------------------------------------

We identified two FDA-approved antiviral drugs (saquinavir and ribavirin) in the coexpression-based drug enrichment analysis (Fig. [3A](#fig3){ref-type="fig"}). Saquinavir, a protease inhibitor ranked 10th in cluster 2, is used to help control HIV infection. Saquinavir has recently been reported as a candidate drug for treating COVID-19 by several individual researchers via molecular docking with 3CLpro, PLpro and spike proteins (Ayman *et al*. [@bib3]; Ruan *et al*. [@bib27]) (Table S3, Supporting Information). By tightly binding to 3CLpro and S proteins, saquinavir can inhibit the replication of this virus both extracellularly and intracellularly (Table S3, Supporting Information).

![Drug repositioning for COVID pneumonia. **(A)** Cogena-based drug repositioning using cluster 2. The top 20 enriched drugs are shown. The names of drugs followed by the cell line, concentration of drug used and instance ID in CMap data are shown on the *y*-axis. The color indicates the degree of statistical significance, and the enrichment score is shown as the -log (*q*-value). **(C)** Venn diagram of upregulated genes by saquinavir and ribavirin and genes in cluster 2. The overlapping numbers of genes and certain gene symbols are shown in some sets.](ftaa036fig3){#fig3}

Ribavirin was ranked 19th in the drug enrichment analysis for cluster 2 (Fig. [3C](#fig3){ref-type="fig"}). Ribavirin can be used in combination with other antiviral medications to treat chronic hepatitis C and for SARS-CoV and MERS-CoV infections (Chong *et al*. [@bib4]; Yin and Wunderink [@bib36]). Ribavirin was reported as a candidate drug by a team of researchers who used molecular docking or protein--protein interaction methods for PLpro and Nsp14 (Gordon *et al*. [@bib9]; Li *et al*. [@bib17]) (Table S3, Supporting Information). More importantly, it has been included as a possible therapeutic drug in the diagnosis and treatment protocol for COVID pneumonia (trial version 5--7) released by the National Health Commission & National Administration of Traditional Chinese Medicine of the P.R. of China on March 3, 2020 (Table S3, Supporting Information) (Commission, N.H., Medicine, N.A.o.T.C [@bib5]), although ribavirin did not perform well at treating the virus in a prior in vitro drug evaluation experiment (Wang *et al*. [@bib31]).

The recovery of the two approved antiviral drugs using our transcriptome-based drug repositioning method indicated the reliability of our method. Moreover, we have successfully applied our drug repositioning method for psoriasis and periodontal disease (Jia *et al*. [@bib12]; Kang *et al*. [@bib13]). Additionally, the consistency among the results produced by two totally different drug repositioning methods, our transcriptome-based and docking-based methods, further validated our results from based on data other than transcriptomics data. The former method was used to find drugs that could restore normal gene expression following viral infection, whereas the latter method aimed to find the drug that directly targets viral or human proteins and inhibits the replication or entry process of the virus. Additionally, one advantage of cogena-based drug repositioning is that it is less computationally intensive than docking methods. Consequently, the results of the cogena-based drug repositioning are robust.

Additionally, the Venn diagram between genes in cluster 2 and the upregulated genes produced by saquinavir and ribavirin is shown in Fig. [3B](#fig3){ref-type="fig"} and Table S4 (Supporting Information). Inositol polyphosphate-5-phosphatase B (INPP5B) was shared between the 3 sets. AP2-associated protein kinase 1 (AAK1) and Arrestin Beta 1 (ARRB1), shared between saquinavir and COVID-19, are involved in endocytosis, and AAK1 is considered a target to inhibit the virus (Richardson *et al*. [@bib24]). Leucyl and cystinyl aminopeptidase (LNPEP), shared between ribavirin and COVID-19, is involved in the renin-angiotensin system, and ACE2, the target of SARS-CoV-2, was also a member of this system. These genes provide insight into the mode of action of the two drugs for treating COVID-19.

Other drugs enriched in the cluster, especially those with a rank higher than that of the two antiviral drugs, could be further investigated to discover more effective drugs for COVID-19. Generally, drugs with similar indications in a cluster possess a higher confidence priority for consideration. Dinoprost, having two instances ranked 1st and 17th, is a smooth muscle activator (Fig. [3A](#fig3){ref-type="fig"}). (-)-Isoprenaline, a bronchodilator useful in obstructive lung diseases, can dilate the bronchi and bronchioles, decreasing resistance in the respiratory airway and increasing airflow to the lungs. Nabumetone, aconitine, dexamethasone, leflunomide and epirizole are anti-inflammatory drugs. Notably, tocilizumab, a biologic binding to interleukin-6 and treatment for cytokine release syndrome, is also recommended in the diagnosis and treatment protocol for COVID pneumonia (trial version 7). Dipivefrine is an antiglaucoma drug, which was also predicted as a candidate drug for treating COVID-19 via a molecular docking method (Ayman *et al*. [@bib3]). Lisuride, pergolide and clozapine are neuropsychiatric agents. We also identified enriched drugs for the other clusters (Figure S5, Supporting Information). Interestingly, the drugs discussed above have not been associated with antiviral activity thus far. This could be due to the principle of our transcriptome-based drug screening that identified drugs that are capable of restoring virus-induced gene expression dysregulation, rather than directly targeting viral or human proteins, as is the case for classical molecule docking methods. Thus, these drugs are of high priority for experimental validation.

CONCLUSION {#sec4}
==========

Based on the COVID group BALF transcriptome data, we showed that several key pathways, such as endocytosis, the lysosome and neutrophil degranulation, in the disease, represent the intense battle between SARS-CoV-2 and humans. We provided several candidate drugs for treating COVID pneumonia using the cogena-based drug repositioning method. A total of two antiviral drugs, saquinavir and ribavirin, were recovered in our results. Coincidentally, these two drugs were also identified by several research groups using molecular docking methods, a totally different but classical strategy for drug development. Furthermore, several candidate drugs for preventing and treating COVID-19 were also identified. Our study shows that cogena is a powerful and efficient drug repositioning tool for emerging infectious diseases, enhances the understanding of SARS-CoV-2-induced disease and importantly provides drug candidates for the prevention and treatment of COVID-19.
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